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Genetic Testing Should Not Be Advocated as a
Diagnostic Tool in Familial Forms of Dementia
To the Editor:
In their article in the January 2000 issue of the Jour-
nal, Finckh et al. advocate the use of a molecular
diagnostic program in patients with early-onset de-
mentia (EOD) and a family history of dementia
(Finckh et al. 2000). In 36 patients with EOD, Finckh
et al. screened for mutations in the presenilin
(PSEN)–1 and -2 genes (MIM 104311 and MIM
600759, respectively), the amyloid-precursor protein
(APP) gene (MIM 104760), and the prion protein
(PRNP) gene (MIM 176640); in 12 patients, they
found mutations that were considered to be disease
causing. Finckh et al. argue that, in the absence of
specific antemortem diagnostic markers for familial
Alzheimer disease (AD) or hereditary prion disease,
molecular testing is important to ensure that treatable
dementias are not missed. Although the findings by
Finckh et al. are of interest, we think that the impli-
cations of these findings for clinical practice are se-
riously limited. We offer several arguments against the
use of genetic testing as a diagnostic tool for the dif-
ferential diagnosis of dementia in general practice.
One significant limit on the usefulness of genetic
testing arises from the distribution and prevalence of
APP, PSEN, and PRNP mutations in EOD. The use-
fulness of a clinical diagnostic test is determined, in
large part, by the composition of the patient popu-
lation. Among the disease-causing mutations found by
Finckh et al., two-thirds were associated with AD, and
one-third occurred in the PRNP gene. This distribu-
tion is surprising and does not reflect the typical clin-
ical experience. The prevalence of early-onset AD is
estimated to be 18.2–41.2 persons per 100,000 at risk,
and that of autosomal-dominant early-onset AD is es-
timated to be 5.3 persons per 100,000 at risk, whereas
the familial forms of the prion diseases, which include
familial Creutzfeldt-Jakob disease, Gerstmann-Stra¨us-
sler-Scheinkers syndrome, and fatal familial insomnia,
have an estimated incidence of only 1/10 million/year
(Haywood 1997; Campion et al. 1999). Even in highly
specialized neurological or geriatric centers, a clini-
cian will not encounter a demented population in
which 33% of patients have prion disease. The rarity
of patients with prion disease underscores the very
atypical composition of the population studied by
Finckh et al. and the limited relevance that their study
has for ordinary diagnostic practice. Furthermore, we
and others have found that, in a population-based
sample, only ∼20% of patients with early-onset fa-
milial AD have a causative mutation (Cruts et al.
1998; Kamimura et al. 1998), whereas Finckh et al.
observed a mutation in 45% of such patients. We ar-
gue that, for clinical practice, the findings in a pop-
ulation-based study are more relevant than those in
a highly selected population.
Our second concern is related to the application of
molecular screening of dementia genes in clinical prac-
tice. In contrast to the mutations in the APP gene,
which are clustered around exons 16 and 17, a large
number of rare mutations in the PSEN genes are
known to be distributed throughout the gene. More
than 50% of these PSEN mutations are genetically
“private”; that is, they are found only in a particular
patient or family (Blacker and Tanzi 1998; Cruts et
al. 1998). As shown by Finckh et al., novel mutations
are still found. Also, previously unknown mutations
are detected in the PRNP gene (Laplanche et al. 1999).
The causative effects of these are difficult to interpret.
A notorious example of misjudging the pathogenicity
of a presumed missense mutation is the Glu318Gly
substitution in the PSEN-1 gene. For example, an 86-
year-old woman fulfilling the National Institute of
Neurological Disorders and Stroke and the Alzheimer
Disease and Related Disorders Association criteria for
probable AD was referred to the Memory Clinic of
Erasmus University Medical School. Her family his-
tory revealed early- and late-onset AD in several first-
degree relatives. We therefore screened for the known
AD-associated genes, and we detected an E318G mu-
tation in the PSEN-1 gene. This substitution was ear-
lier reported as a causative mutation in patients with
familial early-onset AD (Cruts and Van Broeckhoven
1998). In 1999, however, Dermaut et al. demonstrated
that an elderly group of 256 control subjects included
9 carriers of this substitution who were not demented,
results indicating that the frequency in control sub-
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jects was similar to that found in patients (Dermaut
et al. 1999). Rather than being a pathogenic mutation,
the E318G is a rare allele, that is not associated with
either AD or dementia in general and does not influ-
ence the b-amyloid formation. In the absence of any
population data, we might have incorrectly reasoned
that our patient represented a genetic case with late
onset. This example illustrates that, even in familial
cases, studies of a large series of controls should be
performed before conclusions are drawn about the
pathogenicity and penetrance of a particular muta-
tion. For any untreatable disease with a devastating
course, as is the case in AD and prion diseases, the
burden of an incorrect molecular diagnosis should be
prevented by all possible means, since genetic testing
does not have implications for the patient alone but
also discloses predictive information to family mem-
bers, which could influence such issues as life expec-
tancy, insurability, and psychosocial well-being.
We are especially concerned by the emphasis given
to the use of molecular screening of AD genes and the
PRNP gene, in light of the importance of ascertaining
the presence of treatable dementias. First, considera-
bly easier ways to diagnose treatable dementias exist.
In clinical settings it is more straightforward to test
for the presence of a treatable dementia directly (e.g.,
by measuring levels of thyroid-stimulating hormone
level to test for dementia associated with hypothy-
roidism). Second, the presence of a mutation does not
eliminate the possibility of the coexistence of a treat-
able form of dementia. Conditions such as depression,
drug intoxication, vascular dementia, and metabolic
disorders can mimic and coincide with AD, especially
in patients with a long disease course. Even when a
major mutation is present in the family, tests for treat-
able causes of dementia should not be omitted in clin-
ical practice.
Finckh et al. report interesting data on novel mu-
tations. Furthermore, they raise an intriguing question
regarding the use of genetic testing as a diagnostic
tool. However, it is of major importance to recognize
their report’s limited applicability to clinical practice.
We argue that the contribution of genetic testing to
clinical diagnosis is small and does not counterbalance
the problems associated either with interpretation of
any mutation that is found or with secondary effects
on family members. Nevertheless, for scientific rea-
sons, genetic testing is very worthwhile. Testing may
increase our knowledge about the different mutations,
which could have clinical applications in the future.
However, the limits of current knowledge are too
great to justify clinical use of genetic testing in the
diagnostic process.
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Reply to Croes et al.
To the Editor:
Croes et al. (2000 [in this issue]) make the point that
genetic testing as a diagnostic tool shows poor per-
formance in differential diagnosis in general medical
practice. We fully agree with this comment. Therefore,
one of the goals of our study (Finckh et al. 2000) was
to establish criteria that would increase the chance of
identifying a pathogenic mutation in the setting of a
specialized clinic. Indeed, among patients who had
both onset at an early age and positive family history
for early-onset dementia (EOD), diagnostic sequenc-
ing identified disease-relevant mutations in 150% of
the patients analyzed by us. Another notable result of
our study was the finding of four prion mutations
among the 36 EOD patients, which suggested that
atypical forms of prion disease may remain underdi-
agnosed. This assumption is supported by indepen-
dent observations, such as those made by two coau-
thors of the letter by Croes et al. (2000), who found
a PRNP insertion mutation in a patient with both
prion disease and ante mortem diagnosis of familial
Alzheimer disease (FAD) (Dermaut et al. 1998).
We agree with Croes et al. that assessment of the
relevance of previously unknown mutations is a dif-
ficult issue. Nonetheless, in recent screening studies
of FAD, 72%–83% of the sequence changes corre-
sponded to pathogenic mutations already reported
(Kamimura et al. 1998; Campion et al. 1999). In our
study, 58% of the mutations had been previously de-
scribed by others. Repeated identification of any given
rare mutation in a rare disorder, together with the
absence of the mutation in control probands, signif-
icantly increases the likelihood that it has causative
effects.
We were pleased to see that Croes et al. agree with
our conclusion that E318G in PS1 is a nonpathogenic
polymorphism and that they reemphasize the impor-
tance of a careful and critical analysis of the literature.
The importance of early and disease-specific diagnosis
of EOD as a way of identifying treatable forms of
dementia is an issue separate from our assertion that
diagnostic sequencing of the four known EOD genes
may provide important information for proper clinical
and genetic counseling in the early phases of the
disorder.
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